CA
NZ
UK
AU
IND
US
…
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Raphael Pharmaceutical Inc. is a publicly traded, early-stage pharmaceutical company listed on the OTCQB with limited public disclosure about its pipeline and operations. Long-term growth depends on advancing clinical programs, achieving regulatory approvals and securing strategic partnerships or funding, and investors may find potential upside if clinical progress and capitalization improve.
Key risks are early-stage clinical and regulatory uncertainty, likely operating losses and future financing needs that could dilute shareholders and slow development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1.28M | -1.52M | -1.34M | -3.36M | -1.62M |
| Net income | -1.28M | -1.52M | -1.34M | -3.36M | -1.62M |
| Selling general administrative | 0.61M | 0.73M | 0.76M | 2.14M | 0.85M |
| Ebit | - | - | - | -3.32M | -1.63M |
| Ebitda | - | - | - | -3.32M | -1.63M |
| Operating income | -1.25M | -1.51M | -1.33M | -3.32M | -1.63M |
| Interest expense | 0.02M | - | - | - | - |
| Net interest income | -0.02M | -0.00M | -0.00M | -0.04M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.25M | 1.51M | 1.33M | 3.32M | 1.63M |
| Total other income expense net | -0.02M | -0.01M | -0.01M | - | - |
| Net income from continuing ops | -1.28M | -1.52M | -1.34M | -3.36M | -1.62M |
| Net income applicable to common shares | - | - | - | -3.36M | -1.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.05M | 0.03M | 0.24M | 0.33M | 0.42M |
| Other current assets | - | - | - | 0.04M | - |
| Total liab | 1.49M | 0.77M | 0.13M | 0.23M | 0.29M |
| Total stockholder equity | -1.43M | -0.74M | 0.11M | 0.11M | 0.13M |
| Other current liab | - | - | - | 0.22M | - |
| Common stock | - | - | - | 0.16M | 0.13M |
| Capital stock | 0.20M | 0.19M | 0.18M | 0.16M | 0.13M |
| Retained earnings | -10.17M | -8.89M | -7.37M | -6.03M | -2.67M |
| Cash | 0.04M | 0.02M | 0.23M | 0.29M | 0.15M |
| Total current liabilities | 1.49M | 0.77M | 0.13M | 0.23M | 0.29M |
| Net debt | - | 0.02M | - | - | - |
| Short long term debt | 0.03M | 0.04M | - | - | - |
| Property plant equipment | - | - | - | 0.00M | - |
| Total current assets | 0.05M | 0.03M | 0.24M | 0.33M | 0.42M |
| Net tangible assets | - | - | - | 0.11M | 0.13M |
| Net receivables | - | - | - | - | 0.09M |
| Accounts payable | 0.16M | 0.12M | 0.07M | 0.07M | 0.11M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.00M | -0.00M | - |
| Change to liabilities | - | - | - | 0.10M | 0.23M |
| Total cashflows from investing activities | - | - | - | -0.00M | -0.00M |
| Net borrowings | -0.01M | 0.04M | 0.00M | - | 0.17M |
| Total cash from financing activities | 0.24M | 0.32M | 1.15M | 0.90M | 1.48M |
| Change to operating activities | - | - | - | 0.21M | -0.03M |
| Net income | -1.28M | -1.52M | -1.34M | -3.36M | -1.62M |
| Change in cash | 0.03M | -0.21M | -0.06M | 0.14M | 0.06M |
| Begin period cash flow | 0.02M | 0.23M | 0.29M | 0.15M | 0.10M |
| End period cash flow | 0.04M | 0.02M | 0.23M | 0.29M | 0.15M |
| Total cash from operating activities | -0.21M | -0.53M | -1.20M | -0.76M | -1.42M |
| Issuance of capital stock | 0.24M | 0.28M | 1.15M | 0.90M | 1.29M |
| Other cashflows from financing activities | - | - | - | - | 0.01M |
| Change to netincome | - | - | - | 2.29M | 2.29M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.82M | 0.60M | -0.06M | 0.31M | 0.21M |
| Stock based compensation | 0.24M | 0.39M | 0.20M | 2.29M | - |
| Free cash flow | -0.21M | -0.53M | -1.20M | -0.76M | -1.42M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RAPH Raphael Pharmaceutical Inc. |
- -% |
1.51 | - | - | - | 304.45 | -14.44 |
| MKKGY Merck KGaA ADR |
-0.22 0.66% |
33.17 | 21.25 | 14.93 | 3.10 | 2.14 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.76 1.62% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.17 0.80% |
21.02 | - | 10.96 | 0.01 | 1.20 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.85 | - | 10.66 | 0.01 | 1.16 | 23.11 |
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Shlomo Pilo | CEO & Director | 1955 |
| Dr. Igal Louria Hayon | Chief Technology Officer | 1973 |
| Mr. Uri Tadelis | Chief Financial Officer & Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...